DR. KENNETH JOHN COLLEY, MD
Osteopathic Medicine at Clay St, San Francisco, CA

2008003, Feb 14, 2008

May 28, 2004

10/857087

Randall Lee - Hillsborough CA, US
Kenneth Colley - San Francisco CA, US

A61K 38/16, A61K 31/7052, A61P 9/00, C12N 15/63

514012000, 435320100, 514044000

The present invention relates to compositions and methods useful for stimulating or increasing angiogenesis and inducing repair in damaged or diseased tissue, in vivo. More particularly, the present invention is directed to compositions comprising pleiotrophin and methods of inducing and stimulating angiogenesis particularly in ischemic tissue and cardiovascular tissue. The present invention also provides vectors comprising pleiotrophin. These pleiotrophin vectors express pleiotrophin in vivo and are capable of inducing and stimulating angiogenesis in cardiovascular tissue.

5124157, Jun 23, 1992

Aug 18, 1989

7/395717

Kenneth J. Colley - San Francisco CA
Donald R. Wilson - San Francisco CA
Gary W. Cleary - San Mateo CA
Risto Lammintausta - Turku, FI
Harry Jalonen - Turku, FI

Cygnus Therapeutic Systems - Redwood City CA
Farmos Group Ltd. - Turku

A61F 1302

424448

Transdermal administration of dexmedetomidine, the dextrorotatory isomer of medetomidine, is described. The method involves sedating a patient by administering dexmedetomidine to a predetermined area of skin at an administration rate and for a time period effective to achieve the desired level of sedation. A therapeutic system for transdermally administering the drug is also provided. The therapeutic system is in the form of a skin patch which is a laminated composite of a backing layer, an optional anchor adhesive layer, a contact adhesive layer, and one or more additional layers.

5271940, Dec 21, 1993

Mar 27, 1992

7/860300

Gary W. Cleary - San Mateo CA
Kenneth J. Colley - San Francisco CA
Jesus Miranda - Menlo Park CA

Cygnus Therapeutic Systems - Redwood City CA

A61F 1300

424448

A transdermal delivery device has a reservoir containing an active compound, which is kept separate from the delivery layers of the device until administration. At the time of administration, the reservoir is laminated to the delivery layers, or is ruptured to place the active compound, vehicle, and/or permeation enhancers in contact with the delivery layers, which results in administration of the active compound to the skin after a delay period.

5217718, Jun 8, 1993

Sep 17, 1991

7/761408

Kenneth J. Colley - San Francisco CA
Donald R. Wilson - San Francisco CA
Gary W. Cleary - San Mateo CA
Risto Lammintausta - Turku, FI
Harry Jalonen - Turku, FI

Cygnus Therapeutic Systems - Redwood City CA
Farmos Group Ltd. - Turku

A61F 1300

424449

Transdermal administration of dexmedetomidine, the dextrorotatory isomer of medetomidine, is described. The method involves sedating a patient by administering dexmedetomidine to a predetermined area of skin at an administration rate and for a time period effective to achieve the desired level of sedation. A therapeutic system for transdermally administering the drug is also provided. The therapeutic system is in the form of a skin patch which is a laminated composite of a backing layer, an optional anchor adhesive layer, a contact adhesive layer, and one or more additional layers.

2006008, Apr 20, 2006

Sep 8, 2005

11/223741

Randall Lee - Hillsborough CA, US
Kenneth Colley - San Francisco CA, US
James Peacock - San Carlos CA, US

Medlogics Device Corporation - Santa Rosa CA

A61F 2/06

623001390

A stent is provided in combination with a growth factor, specifically pleiotrophin or an analog or derivative thereof, which promotes endothelialization of the stent and re-endothelialization of the stented region of an injured site in a body lumen. In particular applications, the stent is an endolumenal stent and the growth factor promotes healing via endothelialization and substantially prevents restenosis. The growth factor is delivered from the stent formulated as a protein or peptide, or as a gene transfer vector. Methods for the treatment of vascular injury using pleiotrophin are also disclosed.